Tevogen announces planned expansion of TVGN 489’s target population

Tevogen (TVGN) announced a planned expansion of TVGN 489’s target population to include patients 65 and older. Tevogen Bio’s Chief Commercial Officer, Sadiq Khan, MBA, commented, “As the U.S. begins reporting cases of the new COVID variant NB.1.8.1, previously identified in China, which is believed to be more contagious, we have prioritized expansion of clinical manufacturing capacity to addressing significant unmet medical needs.”